After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
But the Astra/Daiichi ADC stumbles in lung cancer.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company is starting four new pivotal trials this year.
RMC-5127 becomes the company’s fourth clinical project.
Tecvayli and Hernexeos might get speedy approval decisions.
